Back to results
US 9,539,201 B2Granted
Selegiline transdermal system
AssigneeKAT Transdermals LLC
InventorsKirti H. Valia, Thomas Mark Rossi, Agis Kydonieus
Life of this patent
Estimating the term…
Abstract
Embodiments of the invention relate generally to the field of transdermal delivery and more specifically to transdermal patches containing selegiline base for the treatment of depression, Parkinson's disease, and other nervous system conditions.
Claims6
A transdermal matrix patch comprising:
- an acrylate copolymer pressure sensitive adhesive which contains vinyl acetate and does not contain any functional groups or crosslinking agents;
- polyvinyl pyrrolidone vinyl acetate copolymers (PVP/VA) at a concentration of about 20 wt %;
- a volatile or non-volatile liquid enhancer at a concentration of 15 wt % or less;
- and
- a quantity of selegiline,
- wherein the transdermal matrix patch is capable of delivering the quantity of selegiline over a period of up to about seven days and at a rate of at least about 12 μg/cm2/hour over a period of at least the first 48 hours.
3 more elements
Dependencies are inferred from the claim text.